Introduction
============

The Ehlers-Danlos syndrome (EDS) is an umbrella term for a group of clinically and genetically heterogeneous connective tissue disorders. Over the past two decades the Villefranche Nosology has been the standard for classifying EDS. It recognized six subtypes, most of which were caused by defects in the primary structure of collagen or collagen-modifying enzymes.^[@bib1]^ Recent discoveries have, however, expanded the pathogenic spectrum to include EDS variants that are caused by defects in both noncollagenous extracellular matrix proteins and intracellular processes.^[@bib2],\ [@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9],\ [@bib10]^ This has led to an EDS reclassification: a task that was recently accomplished by an international EDS consortium.^[@bib11]^

Skin hyperextensibility and joint hypermobility are the clinical hallmarks of EDS, but more variable signs of soft connective tissue fragility are helpful in discriminating between the different types. Historically, arterial aneurysm and dissection have been synonymous with the vascular type of EDS (vEDS). This type of EDS is characterized by the presence of a thin, translucent skin, which bruises very easily, and joint hypermobility, which is often confined to the small joints. The clinical picture is, however, dominated by a remarkable vascular fragility that leads to spontaneous rupture of blood vessel walls, often without preceding vascular dilatation or aneurysm formation. Other life-threatening complications include rupture of the gastrointestinal (GI) tract, gravid uterus, or other internal organs, such as liver or spleen.^[@bib12]^ The calculated median survival for vEDS patients is 48 years, with most deaths resulting from arterial rupture.^[@bib13]^ Complications are rare in childhood, but 25% will have a first complication by the age of 20 years, and more than 80% will have had at least one complication by the age of 40 years. Therapeutic interventions are limited to symptomatic measures.^[@bib14]^ Hitherto, the only evidence-based treatment strategy has been the administration of celiprolol, a cardioselective β-blocker with β2 agonist vasodilatory properties, which has been reported to reduce heart rate and pulsatile pressures in essential hypertension and could therefore decrease the continuous and pulsatile mechanical stress on collagen fibers within the arterial wall.^[@bib15],\ [@bib16]^ vEDS is caused by heterozygous mutations in the type III procollagen-encoding gene *COL3A1*.^[@bib17]^ Genotype--phenotype correlations have been extensively investigated. Substitution of triple helical glycine residues and splice donor site mutations, leading to exon skipping, are generally associated with a shorter life expectancy, whereas mutations leading to *COL3A1* haploinsufficiency are usually associated with a milder phenotype, a delay in the onset of complications, and a longer life expectancy.^[@bib18],\ [@bib19]^

Vascular complications, including arterial aneurysms and ruptures, subcutaneous hematomas, gum bleeding, and prolonged perioperative and menstrual bleeding, have also been described in other, "nonvascular" subtypes of EDS.^[@bib20],\ [@bib21]^ Most of these reports are anecdotal, and the occurrence of such complications in the different EDS subtypes is not well documented. In view of the vast clinical and genetic heterogeneity of EDS, it may therefore be difficult for clinicians to predict, for a specific EDS patient, whether vascular complications should be taken into account, and how patients should be followed.

We reviewed the medical literature on EDS in a systematic manner to better document the nature of vascular complications in patients with a nonvascular EDS diagnosis confirmed via molecular testing. This review will help familiarize clinicians with the spectrum of vascular complications in nonvascular EDS subtypes as well as guide follow-up and management.

Materials and methods
=====================

Study design
------------

This systematic review was designed and carried out in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement for reporting systematic reviews.^[@bib22]^

Search strategy
---------------

The aim of this study was to collect all available data on vascular complications in the nonvascular EDS subtypes described in the updated EDS classification ([Table 1](#tbl1){ref-type="table"}). We queried the PubMed and Web of Science databases, taking into account the different notations for the EDS subtypes (e.g., classic versus classical). For classical EDS (*COL5A1/2*), for example, the following keywords were used: Ehlers-Danlos syndrome, classic\*, *COL5A1*, *COL5A2*, Ehlers-Danlos syndrome type I, Ehlers-Danlos syndrome type II. All keywords for each EDS subtype are outlined in [Table 1](#tbl1){ref-type="table"}. Based on these keywords, search strings to query the respected databases for, for example, classical EDS (*COL5A1/2*) were constructed as follows: ("Ehlers-Danlos syndrome"\[Title/Abstract\] AND (classic\*\[Title/Abstract\] OR COL5A1\[Title/Abstract\] OR COL5A2\[Title/Abstract\])) OR "Ehlers-Danlos syndrome type I"\[Title/Abstract\] OR "Ehlers-Danlos syndrome type II"\[Title/Abstract\]. To exclude nonrelevant references, queries were restricted to "title" and "abstract" in PubMed and "topic" in Web of Science. All search strings are outlined in [Supplementary Table S1](#sup1){ref-type="supplementary-material"} online. The Leiden Open Variation Database (<http://www.lovd.nl/3.0/home>) was queried for additional references. All references published from inception until 31 May, 2017 were eligible for inclusion in this review. A bibliography was created using EndNote X7 (Thomson Reuters, New York, NY).

Screening process and eligibility criteria
------------------------------------------

Primary literature screening was performed by two investigators (S.D. and T.V.D.), independently, according to the following inclusion criteria: (i) population: nonvascular subtypes of EDS, (ii) language: English, (iii) papers: no short conference proceedings or meeting abstracts, and (iv) availability of the full text. Next, eligibility for inclusion in the review after full-text screening of the remaining papers was further assessed using the following criteria: descriptions of both (i) the patient's phenotype and (ii) the pathogenic genetic defect. Patients for whom only linkage to a gene or a biochemical diagnosis was demonstrated were excluded. Hypermobile EDS was also not included, since its genetic etiology remains unknown and because---prior to the updated 2017 classification on EDS^[@bib11]^---its definition covered a broad clinical spectrum, with variable signs of connective tissue fragility that closely overlapped with joint hypermobility syndrome. The following types of studies were considered: clinical trials, case-control studies, cross-sectional studies, cohort studies, case series, and case reports published in peer-reviewed scientific journals. Excluded were cell culture laboratory studies, animal studies, and reviews. Titles and abstracts were checked with regard to the predefined eligibility criteria. Abstracts with unclear methodology were included in full-text assessment to avoid exclusion of potentially relevant papers.

Quality assessment
------------------

Quality assessment tools for case series, case-control, cross-sectional, and cohort studies are available from the National Heart, Blood, and Lung Institute (Bethesda, MD) (<https://www.nhlbi.nih.gov/>). Quality assessment tools for case reports are available from the Joanna Briggs Institute (Adelaide, Australia) (<http://joannabriggs.org/>). Each study was classified into one of the following groups: (i) good if all quality criteria were judged as "present," (ii) fair if one or more key domains were "unclear," or (iii) poor if one or more key domains were "absent" ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Data extraction and aggregation
-------------------------------

Data extraction and aggregation were performed by a single investigator (S.D.). Uncertainties were resolved through discussion with the principal investigator (F.M.). The following data, if available, were extracted from the included references: (i) study characteristics (authors and year of publication), (ii) patient attributes (patient and family identifiers, age at time of referral or vascular complication, and relevant comorbidities), (iii) vascular features (type and location of vascular complication, recurrence, management, and cause of death), and (iv) mutation. If a patient or family was described more than once, the most informative reference was used for data collection. The spectrum of vascular complications was further categorized into (i) hematomas, (ii) intracranial hemorrhages, (iii) arterial dissections, (iv) arterial aneurysms, (v) GI bleedings, (vi) perioperative hemorrhages, and (vii) sporadic vascular complications. The data collection on hematomas included only those that occurred spontaneously or from minor trauma or were described as severe in nature (e.g., "large," "massive," "repeated," "profuse"). Easy bruising was not included in this study for many reasons. It is often described in a nondescriptive manner, and as a symptom it is often overreported by both patients and caregivers. We therefore felt that including easy bruising would lead to an overrepresentation of vascular complications in nonvascular EDS. The primary outcome of these data-processing procedures was the derivation of the total number of nonvascular EDS patients, along with the number of patients reported with, respectively, none, one, or more than one vascular complication. The secondary outcome included the number, type, and location of reported vascular complications.

Results
=======

Search results and study characteristics
----------------------------------------

A flow diagram of the search selection process is depicted in [Figure 1](#fig1){ref-type="fig"}. Our search strategy identified 809 unique papers, 547 of which were excluded after primary screening based on title and abstract. From the remaining 262 papers selected for full-text screening, 112 papers were found to meet the predefined inclusion criteria ([Figure 1](#fig1){ref-type="fig"}). All included papers are listed in [Supplementary Table S2](#sup1){ref-type="supplementary-material"} and a brief overview of all included studies and patients is presented in [Table 2](#tbl2){ref-type="table"}. The types of studies reported by these papers included mainly case reports (*n* = 51) and series (*n* = 59), a cross-sectional study (*n* = 1), and a cohort study (*n* = 1). There was a quality assessment of the included papers, of which 38 were classified as good, 43 as fair, and 31 as poor. None of them were rejected based on assessed quality alone, so that a large population could be obtained, based on which it is possible to draw firm conclusions. These 112 papers report on 467 patients (197 males, 238 females, and 32 not defined) from 342 unrelated families, and include 29 papers on classical EDS (cEDS; *COL5A1/2*: *n* = 25; *COL1A1* p.(Arg312Cys): *n*=4),^[@bib23],\ [@bib24],\ [@bib25],\ [@bib26],\ [@bib27],\ [@bib28],\ [@bib29],\ [@bib30],\ [@bib31],\ [@bib32],\ [@bib33],\ [@bib34],\ [@bib35],\ [@bib36],\ [@bib37],\ [@bib38],\ [@bib39],\ [@bib40],\ [@bib41],\ [@bib42],\ [@bib43],\ [@bib44],\ [@bib45],\ [@bib46],\ [@bib47],\ [@bib48],\ [@bib49],\ [@bib50],\ [@bib51]^ 6 on classical-like EDS (clEDS; *TNXB*),^[@bib52],\ [@bib53],\ [@bib54],\ [@bib55],\ [@bib56],\ [@bib57]^ three on cardiac-valvular EDS (cvEDS; *COL1A2*),^[@bib58],\ [@bib59],\ [@bib60]^ ten on arthrochalasia EDS (aEDS; *COL1A1/2*),^[@bib61],\ [@bib62],\ [@bib63],\ [@bib64],\ [@bib65],\ [@bib66],\ [@bib67],\ [@bib68],\ [@bib69],\ [@bib70]^ six on dermatosparaxis EDS (dEDS; *ADAMTS2*),^[@bib71],\ [@bib72],\ [@bib73],\ [@bib74],\ [@bib75],\ [@bib76]^ 22 on kyphoscoliotic EDS (kEDS; *PLOD1*: *n* = 17, *FKBP14*: *n* = 5),^[@bib4],\ [@bib77],\ [@bib78],\ [@bib79],\ [@bib80],\ [@bib81],\ [@bib82],\ [@bib83],\ [@bib84],\ [@bib85],\ [@bib86],\ [@bib87],\ [@bib88],\ [@bib89],\ [@bib90],\ [@bib91],\ [@bib92],\ [@bib93],\ [@bib94],\ [@bib95],\ [@bib96],\ [@bib97]^ ten on brittle cornea syndrome (BCS; *ZNF469*: *n* = 5; *PRDM5*: *n*=5),^[@bib2],\ [@bib98],\ [@bib99],\ [@bib100],\ [@bib101],\ [@bib102],\ [@bib103],\ [@bib104],\ [@bib105],\ [@bib106]^ 11 on spondylodysplastic EDS (spEDS; *B4GALT7*: *n* = 5; *B3GALT6*: *n* = 4; *SLC39A13*: *n* = 2),^[@bib5],\ [@bib8],\ [@bib9],\ [@bib107],\ [@bib108],\ [@bib109],\ [@bib110],\ [@bib111],\ [@bib112],\ [@bib113],\ [@bib114]^ 12 on musculocontractural EDS (mcEDS; *CHST14*: *n* = 11; *DSE*: *n* = 1),^[@bib6],\ [@bib7],\ [@bib115],\ [@bib116],\ [@bib117],\ [@bib118],\ [@bib119],\ [@bib120],\ [@bib121],\ [@bib122],\ [@bib123],\ [@bib124]^ two on myopathic EDS (mEDS; *COL12A1*),^[@bib125],\ [@bib126]^ and one on periodontal EDS (pEDS; *C1R/S*).^[@bib127]^ One paper that fulfilled the inclusion criteria was withheld because it contained data for a patient described more thoroughly in another paper.^[@bib128]^

Nonvascular EDS with vascular complications
-------------------------------------------

Seventy-seven of 467 (17%) individuals with nonvascular EDS (age: ranging from birth to 62 years) were reported with a total number of 100 vascular complications. Vascular complications were, in terms of percentage, most frequently reported in mcEDS-*DSE* (2/3, 67%), mcEDS-*CHST14* (27/43, 63%), clEDS (10/19, 53%), cvEDS (2/5, 40%), dEDS (5/15, 33%), cEDS-*COL1A1* (3/12, 25%), kEDS-*FKBP14* (2/10, 20%), kEDS-*PLOD1* (8/54, 15%), spEDS-*SLC39A13* (1/8, 13%), cEDS-*COL5A1/2* (12/110, 11%), aEDS (1/17, 6%), pEDS (3/55, 5%), and spEDS-*B3GALT6* (1/25, 4%) ([Figure 2a](#fig2){ref-type="fig"}). Of these 77 individuals, 14 (18%) suffered more than one complication, with an average of 1.3, ranging from one to six complications per case. This, however, corresponds to only 3% (14/467) of all individuals included in this systematic review. The occurrence of multiple complications was reported most frequently in mcEDS-*CHST14* (8/43, 19%) ([Table 3](#tbl3){ref-type="table"}). No vascular complications were recorded in spEDS-*B4GALT7,* BCS and mEDS.

Mortality
---------

Overall, death due to vascular complications was reported in eight individuals (8/467, 2%). In cEDS-*COL5A1*, three adult patients died from rupture of a large or medium-sized artery (mean age: 35 years, range 28--43 years)^[@bib25]^ and one 9-year old patient died from multiorgan failure secondary to the rupture of an aneurysm of the superior mesenteric artery.^[@bib31]^ One patient with cvEDS died from bleeding complications during aortic valve replacement surgery at the age of 45 years.^[@bib60]^ In dEDS, one patient died shortly after birth from severe hemorrhage and shock.^[@bib72]^ One patient with mcEDS-*CHST14* died from a large intracerebral hemorrhage at the age of 59 years, and, finally, one with kEDS-*PLOD1* died from an arterial rupture at an unspecified site at an unknown age.^[@bib89],\ [@bib116]^

Vascular phenotypes and management
----------------------------------

To provide an overview of the type of vascular complications in nonvascular EDS patients, each reported complication (*n* = 100) was categorized as either (i) hematoma (53/100, 53%), (ii) intracranial hemorrhage (18/100, 18%), (iii) spontaneous arterial dissection (16/100, 16%), (iv) arterial aneurysm (5/100, 5%), (v) GI bleeding (1/100, 1%), (vi) perioperative hemorrhage (5/100 5%), or (vii) sporadic vascular complication (2/100, 2%). An overview of the vascular phenotypes is presented in [Figure 2b](#fig2){ref-type="fig"}, and [Table 3](#tbl3){ref-type="table"} summarizes the reported type of complications per nonvascular EDS subtype.

### Hematoma

The most frequent of all vascular complications was the formation of hematomas (53/100, 53%), either spontaneously (10/53, 19%) or after minor trauma (32/53, 60%), such as a minor fall. They were reported primarily in mcEDS patients (25/46, 54%) (*DSE*: 2/3, 67% *CHST14*: 23/43, 53%)^[@bib6],\ [@bib115],\ [@bib116],\ [@bib117],\ [@bib118],\ [@bib119],\ [@bib120],\ [@bib121],\ [@bib122]^ and clEDS patients (10/19, 53%),^[@bib53],\ [@bib55],\ [@bib56],\ [@bib57]^ and, to a lesser extent, in patients with dEDS (2/15, 13%)^[@bib72],\ [@bib74]^ and cEDS-*COL5A1* (3/110, 3%).^[@bib34],\ [@bib38]^ Most hematomas were subcutaneous (41/53, 77%), but epidural, spinal, scalp, and stomach wall hematomas were reported as well. Management was reported only in mcEDS, where some hematomas from minor trauma required transfusion (*n* = 7), surgical drainage (*n* = 6), and/or admittance to the intensive care unit (*n* = 3). One mcEDS-*CHST14* patient presented with a spontaneous hematoma and was treated with emergency surgical drainage and transfusion.^[@bib115]^

### Intracranial hemorrhage

The second most frequently reported vascular complication was intracranial hemorrhage (18/100, 18%), including 10 intracerebral, three subdural, one subarachnoid, one epidural, and three unspecified hemorrhages. dEDS denoted a high risk of intracerebral hemorrhage, affecting 20% of the patients (3/15), mostly at birth.^[@bib73],\ [@bib76]^ Intracranial hemorrhages were also reported in mcEDS-*CHST14* (4/43, 9%),^[@bib116],\ [@bib118],\ [@bib120]^ kEDS-*PLOD1* (4/54, 7%),^[@bib78],\ [@bib80],\ [@bib86],\ [@bib87]^ pEDS (2/55, 4%),^[@bib127]^ spEDS (2/61, 3%) (*SLC39A13*: 1/8, 13% *B3GALT6*: 1/25, 4%),^[@bib5],\ [@bib9]^ and cEDS-*COL5A1* (1/110, 1%).^[@bib25]^

### Arterial dissection

Overall, 13 patients suffered a total of 16 arterial dissections (16/100, 16%): eight patients with cEDS (8/122, 7%) (*COL1A1*: 2/12, 17% *COL5A1*: 6/110, 5%),^[@bib25],\ [@bib27],\ [@bib33],\ [@bib49],\ [@bib50]^ seven patients with kEDS (7/64, 11%) (*PLOD1*: 5/54, 9% *FKBP14*: 2/10, 20%),^[@bib79],\ [@bib80],\ [@bib89],\ [@bib95],\ [@bib97]^ and one with cvEDS (1/5, 20%).^[@bib60]^ Dissections occurred most frequently in medium-sized or large arteries, including the iliac, femoral, renal, celiac, hypogastric, subclavian, superior mesenteric, brachial, and coronary arteries. Aortic dissection was reported in one patient with cEDS-*COL5A1*.^[@bib25]^ Data about management is limited and mostly anecdotal, but seven of these dissections were treated surgically and two with endovascular techniques.^[@bib25],\ [@bib27],\ [@bib49],\ [@bib79],\ [@bib95],\ [@bib97]^

### Arterial aneurysm

Arterial aneurysms were reported in five patients (5/100, 5%), including cEDS (4/122, 3% *COL5A1*: 3/110, 3% *COL1A1*: 1/12, 8%) and kEDS-*PLOD1* (1/54, 2%).^[@bib25],\ [@bib28],\ [@bib30],\ [@bib31],\ [@bib82]^ Large (*n* = 1) and medium-sized (*n* = 3) arteries were affected and aortic root dilatation was described in one cEDS patient.^[@bib28]^ Three aneurysms were reported as having ruptured, two in connection with cEDS-*COL5A1* and one with kEDS-*PLOD1*; they were managed using endovascular techniques.^[@bib30],\ [@bib31],\ [@bib82]^ One patient underwent surgery twice and was followed up using regular computed tomography angiography.^[@bib25]^

### Gastrointestinal bleeding

Severe GI bleeding was reported in one cEDS-*COL5A2* (1/110, 1%) patient, who suffered a perforation of the terminal ileum at birth and was treated with an ileostomy.^[@bib23]^ Several more common GI problems are described below.

### Perioperative hemorrhage

Perioperative hemorrhage (5/100, 5%) was reported in two patients with mcEDS-*CHST14* (2/43, 5%) during a laparoscopic procedure and surgery for dislocations,^[@bib63],\ [@bib118],\ [@bib123]^ in one patient with aEDS (1/18, 6%) who bled excessively at surgery (unspecified),^[@bib63]^ in one patient with pEDS (1/55, 2%) who had a profuse bleeding after hysterectomy,^[@bib127]^ and in one cvEDS patient (1/5, 20%), who underwent aortic valve replacement surgery and died from it at the age of 45 years.^[@bib60]^

### Sporadic vascular complications

One cEDS-*COL5A1* patient (1/110, 1%) was reported with a pulmonary artery hypoplasia,^[@bib28]^ and one dEDS patient (1/15, 7%) presented with a pleural serohemorrhagic effusion of the left lung.^[@bib74]^

### Common and aspecific vascular features

Several vascular and bleeding complications, which are presumed to be relatively frequent in the general population, have been reported in various EDS subtypes. Since these vascular features are potentially aspecific, we listed them as complementary but did not add them to the total number of complications.

Menometrorrhagia was reported in two patients with cEDS-*COL5A1* (2/65 females, 3%)^[@bib28]^ and postpartum hemorrhaging was reported in one patient with aEDS (1/12 females, 8%) after the birth of each of her children and in one clEDS (1/12 females, 8%).^[@bib53],\ [@bib65]^ The severity of the latter was not described.

Minor GI bleeding was reported in two clEDS (2/18, 11%),^[@bib53],\ [@bib57]^ two dEDS (2/15, 13%),^[@bib71]^ two mcEDS-*CHST14* (2/43, 5%),^[@bib115]^ and one pEDS (1/55, 2%) patients.^[@bib127]^ Two dEDS patients suffered rectal prolapse with anal bleeding,^[@bib71]^ and one clEDS patient had a gastric ulcer.^[@bib53]^ The origin of the bleeding was not specified in the other clEDS and the pEDS patient.

Venous complications such as varicose veins and deep venous thrombosis (DVT) were reported in a number of patients. In cEDS, seven patients presented with varicose veins (7/122, 6% *COL5A1*: 4/110, 4% *COL1A1*: 3/12, 25%) and three with a DVT (3/110, 3%).^[@bib28],\ [@bib33],\ [@bib42],\ [@bib44],\ [@bib48]^ Two patients with spEDS-*SLC39A13* (2/8, 25%) presented with varicose veins,^[@bib5]^ and one patient with kEDS-*PLOD1* (1/54, 2%) presented with a DVT from compression stasis, which was treated by fasciotomy.^[@bib93]^ All of these patients were over the age of 40 years, except for the kEDS-*PLOD1* patient, who presented with a DVT at the age of 15 years.^[@bib93]^

Five patients were reported with small bleedings: three of these suffered from gum bleeding (mcEDS-*CHST14*: 2/43, 5% cEDS-*COL5A1*: 1/110, 1%),^[@bib28],\ [@bib118],\ [@bib123]^ and two dEDS patients suffered from epistaxis (2/15, 13%).^[@bib71],\ [@bib129]^

Discussion
==========

Vascular complications are an important finding in nonvascular subtypes of EDS. Overall, 77/467 (17%) of the patients included in this study presented with relatively severe vascular complications. In line with the clinical and genetic heterogeneity of this group of disorders, there are important differences in the number, severity, and type of complications associated with the different EDS subtypes ([Table 3](#tbl3){ref-type="table"}). Vascular complications, for example, are most frequently reported in mcEDS (*CHST14/DSE*) and in clEDS (*TNXB*), being present in about two thirds and half of the patients, respectively. In contrast, to date no vascular complications have been reported for spEDS-*B4GALT7*, BCS, and mEDS.

In mcEDS and clEDS, the vascular phenotype shows a large predominance of hematomas. In clEDS, hematomas are mostly spontaneous and subcutaneous, whereas in mcEDS they mostly occur after minor trauma, and also affect other locations besides subcutaneous tissues (e.g., scalp, spine, and buttock). Furthermore, these hematomas are different from the commonly reported easy bruising in EDS and the large hematomas in clEDS, because they can be severe in nature and sometimes necessitate surgery and blood transfusion. Of note, four mcEDS-*CHST14* patients were reported to have intracranial bleeding, of which one person died at the age of 59 years. Therefore, this appears to be a rare but important complication of mcEDS.

cEDS, cvEDS, dEDS, and kEDS are associated with a lower, but nonetheless important risk of vascular complications. Moreover, in these subtypes, the majority of vascular complications are severe and potentially life-threatening, and include intracranial hemorrhages, arterial aneurysms, and arterial dissections. The latter complications each account for approximately 5--16% of all reported vascular complications in nonvascular EDS. Arterial aneurysms have been reported in a few patients with cEDS (*COL5A1/COL1A1*) and kEDS-*PLOD1*. Arterial dissections are most frequently reported in kEDS-*FKBP14* (20% of 10 kEDS-*FKBP14* patients) and cEDS due to *COL1A1* p.(Arg312Cys) (17% of 12 cEDS-*COL1A1* patients), and to a lesser extent in kEDS-*PLOD1* (9% of 54 kEDS-*PLOD1* patients) and cEDS-*COL5A1* (5% of 110 cEDS-*COL5A1* patients). One patient with cvEDS was also reported to have an arterial dissection. As in vEDS, these aneurysms and dissections mostly affect large and medium-sized arteries, such as the iliac, femoral, renal, celiac, hypogastric, subclavian, superior mesenteric, brachial, and coronary arteries. Aortic dissection was reported in only one patient with cEDS-*COL5A1*. Arterial aneurysms and dissections have not been reported for any of the other EDS subtypes. Overall, arterial aneurysms and dissections are significantly less frequently reported than in vEDS, where such complications are reported in approximately 50% of patients.^[@bib18],\ [@bib130]^

In dEDS, 25% of the patients suffered from intracranial hemorrhage, especially in the perinatal period. Intracranial hemorrhage was also reported in a range of other subtypes, including kEDS-*PLOD1* (also in the perinatal period), mcEDS-*CHST14*, pEDS, spEDS (*SLC39A13* and *B3GALT6*), and cEDS-*COL5A1* (at ages ranging from 2 to 62 years). Despite a relatively high occurrence of these severe vascular complications, reported mortality was only 2% (8/467).

In addition to these severe and potentially life-threatening problems, several other, and often minor, bleeding manifestations, such as gynecological and GI bleedings, perioperative hemorrhage, varicose veins, DVT, gum bleeding, and epistaxis have been reported in a variety of EDS subtypes, including cEDS, clEDS, aEDS, dEDS, kEDS-*PLOD1*, spEDS-*B3GALT6*, mcEDS-*CHST14*, and pEDS. However, it should be noted that these bleeding manifestations are also relatively common in the general population: e.g., the estimated incidence for menometrorrhagia is 10--20%,^[@bib131]^ 3--10% for perioperative hemorrhage,^[@bib132]^ 10--15% and 20--25% for varicose veins in men and women respectively.^[@bib133]^ As such, these manifestations were not counted toward the total number of vascular complications, but were merely listed as complementary in this review.

Data on treatment and treatment outcome of arterial complications in nonvascular EDS are very limited, being reported in only 11 of 77 (14%) patients with complications. In the case of arterial aneurysms and dissections, these patients underwent endovascular stenting (*n* = 5), classical surgery (*n* = 4), or conservative treatment (*n* = 2). It is difficult, based on the available data, to formulate guidelines for the surveillance and follow-up of arterial aneurysms in nonvascular EDS. Especially for subtypes associated with increased risk for arterial dissections and aneurysms, surveillance strategies based on noninvasive imaging, such as ultrasound, magnetic resonance angiography, and computed tomography angiography with or without venous contrast, could be recommended, as in the care guidelines for vEDS.^[@bib134]^ Guidelines for cardiovascular care and surgery for Marfan and Loeys-Dietz syndromes, including annual cardiovascular imaging, blood pressure--lowering medication (e.g., angiotensin receptor blockers, β-blockers, or angiotensin-converting enzyme inhibitors), and surgery when approaching surgical thresholds for aortic root dimensions or acute dissection, could also be used until EDS subtype-specific recommendations are available.^[@bib135],\ [@bib136]^ There are no reports about the use of celiprolol, the β-blocker that has proven to delay vascular complications in vEDS.^[@bib15],\ [@bib16]^ One could argue, however, for its use in EDS subtypes with an increased risk of arterial rupture and/or aneurysm (e.g., cEDS, kEDS). Another drug that has anecdotally been reported to be useful in treating or preventing bleeding episodes and/or hematomas in several EDS subtypes, such as mcEDS, kEDS, and vEDS, is the procoagulant desmopressin (DDAVP).^[@bib116],\ [@bib137],\ [@bib138]^

The study's inherent limitations should be taken into account when interpreting the results. First, the systematic and predefined search strategy aimed to identify all potentially relevant studies, but the risk of selection bias is not negligible. Second, extensive natural history studies on EDS are rare: the data summarized here are derived mostly from either case reports (*n* = 51) or case series (*n* = 59), which are prone to publication and selection bias, because the cases are mainly self-selected. Third, asymptomatic features (e.g., silent aneurysms) are often not actively screened for such retrospective studies. Finally, for some subtypes, such as dEDS, kEDS-*FKBP14*, spEDS-*B4GALT7*, mcEDS-*DSE*, and mEDS, very few patients have been reported to date. As such, it is likely that the current review is only a mere approximation of the occurrence and spectrum of vascular complications in nonvascular EDS.

In conclusion, vascular complications are important and sometimes severe in some nonvascular EDS subtypes. They are found mainly in mcEDS, clEDS, dEDS, kEDS, and cEDS. Hematomas are most frequently reported (53%) and predominate mcEDS and clEDS. Serious, potentially life-threatening complications such as intracranial hemorrhage, arterial aneurysms, and dissections of large and medium-sized arteries, account for approximately 18, 5 and 16% of vascular complications, respectively, and are most frequently seen in dEDS (intracranial hemorrhage), cEDS (arterial dissections and aneurysms), and kEDS (arterial dissections). No complications were reported yet in spEDS-*B4GALT7*, BCS, and mEDS. Given the relatively high occurrence of vascular complications in EDS patients, referral for cardiovascular assessment and regular follow-up imaging may be required upon diagnosis, especially for cEDS, dEDS, and kEDS. If vascular complications are detected, the type and location of a complication will guide treatment options. However, to optimize management and care guidelines, future research should be focused on more systematic documentation of vascular and bleeding complications and their management in natural history studies and registries.
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![**Flow diagram presenting the search and selection process.**](gim2017138f1){#fig1}

![**Vascular complications in nonvascular EDS.** (**a**) The number of patients with vascular complications is presented for each nonvascular EDS subtype in terms of percentage. The ratios relate to the total number of patients with vascular complication(s), to the total number per subtype. (**b**) The number of each type of complication is presented in terms of percentage. EDS, Ehlers-Danlos syndrome (for the definitions of the various subtypes of EDS, see Table 1); GI, gastrointestinal.](gim2017138f2){#fig2}

###### Overview of all nonvascular subtypes of the Eherls-Danlos syndrome included in this systematic review

  EDS type                        IP      Gene                             Protein                                           Keywords
  ------------------------------- ------- -------------------------------- ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classical (cEDS)                AD      *COL5A1/2* *COL1A1*              Type V collagen Type I collagen (p.(Arg312Cys))   Ehlers-Danlos syndrome, classic\*, *COL5A1*, *COL5A2*, Ehlers-Danlos syndrome type I, Ehlers-Danlos syndrome type II Ehlers-Danlos syndrome, *COL1A1*
  Classical-like (clEDS)          AR      *TNXB*                           Tenascin X                                        Ehlers-Danlos syndrome, *TNXB*, tenascin-x
  Cardiac-valvular (cvEDS)        AR      *COL1A2*                         Type I collagen (total absence of α2 chain)       Ehlers-Danlos syndrome, *COL1A2*
  Arthrochalasia (aEDS)           AD      *COL1A1/2*                       Type I collagen (*N*-propeptide processing)       Ehlers-Danlos syndrome, arthrochalasia, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome type VIIB
  Dermatosparaxis (dEDS)          AR      *ADAMTS2*                        ADAMTS2                                           Ehlers-Danlos syndrome, dermatospara\*, *ADAMTS2*, Ehlers-Danlos syndrome type VIIC
  Kyphoscoliotic (kEDS)           AR      *PLOD1* *FKBP14*                 LH1 FKBP22                                        Ehlers-Danlos syndrome, kyphoscolio\*, *PLOD1*, Ehlers-Danlos syndrome type VIA Ehlers-Danlos syndrome, *FKBP14*
  Brittle cornea syndrome (BCS)   AR      *ZNF469* *PRDM5*                 ZNF469 PRDM5                                      Brittle cornea syndrome, *ZNF469*, *PRDM5*
  Spondylodysplastic (spEDS)      AR      *B4GALT7* *B3GALT6* *SLC39A13*   β4GalT7 β3GalT6 ZIP13                             Ehlers-Danlos syndrome, progeroid, *B4GALT7* Ehlers-Danlos syndrome, progeroid, *B3GALT6* Ehlers-Danlos syndrome, spondylocheirodysplas\*, *SLC39A13*
  Musculocontractural (msEDS)     AR      *CHST14* *DSE*                   D4ST1 DSE                                         Ehlers-Danlos syndrome, musculocontractural, *CHST14*, *DSE*, Ehlers-Danlos syndrome type VIB, adducted thumb-clubfoot syndrome, Ehlers-Danlos syndrome Kosho type, D4ST1-deficient Ehlers-Danlos syndrome
  Myopathic (mEDS)                AR/AD   *COL12A1*                        Type XII collagen                                 Ehlers-Danlos syndrome, *COL12A1*
  Periodontal (pEDS)              AD      *C1R/S*                          C1r and C1s                                       Ehlers-Danlos syndrome, periodontal, *C1R*, *C1S*

AD, autosomal dominant; AR, autosomal recessive; EDS, Ehlers-Danlos syndrome; IP, inheritance pattern.

###### Overview of all studies and patients included in this systematic review

  EDS subtype          Study                                                     Quality                         Gender                                    Age       Race/ethnicity
  -------------------- --------------------------------------------------------- ------------------------------- ----------------------------------------- --------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  cEDS (*COL5A1/2*)    Case report (13), case series (11), cross-sectional (1)   Good (8), fair (12), poor (5)   M (48), F (59), ND (3)                    2--67 y   Caucasian, Turkish, Asian, black, white
  cEDS (*COL1A1*)      Case report (1), case series (3)                          Good (3), fair (1)              M (6), F (6)                              5--69 y   Caucasian, Hispanic
  clEDS (*TNXB*)       Case report (3), case series (3)                          Good (3), fair (2), poor (1)    M (8), F (11)                             6--53 y   Dutch
  cvEDS (*COL1A2*)     Case report (2), case series (1)                          Good (1), fair (2)              M (3), F (2)                              0--45 y   Portuguese
  aEDS (*COL1A1/2*)    Case report (8), case series (2)                          Good (4), fair (4), poor (2)    M (4), F (12), ND (1)                     0--32 y   German, Japanese, Chinese, South African, Libyan
  dEDS (*ADAMTS2*)     Case report (2), case series (4)                          Good (2), fair (3), poor (1)    M (9), F (6)                              0--7 y    Caucasian, Turkish, Pakistani, Ashkenazi
  kEDS (*PLOD1*)       Case report (10), case series (6), cohort (1)             Good (5), fair (8), poor (4)    M (22), F (23), ND (9)                    0--7 y    Macedonian, Serbian, Iranian, Somali, Iraqi, Egyptian, Arab, Turkish, Albanian, Bosnian, Greek, Italian, Spanish, French, Dutch, German, North American, Mexican-American, white, Caucasian
  kEDS (*FKBP14*)      Case report (2), case series (3)                          Good (3), poor (2)              M (5), F (5)                              2--48 y   Caucasian, Austrian, Italian, German, French, Turkish
  BCS (*ZNF469*)       Case series (5)                                           Good (1), fair (2), poor (2)    M (13), F (22)                            0--28 y   British, Indian, Pakistani, Saudi Arabian, Syrian, Yemeni, Palestinian, Tunisian
  BCS (*PRDM5*)        Case report (3), case series (2)                          Fair (2), poor (3)              M (4), F (12), ND (4)                     2--26 y   Saudi Arabian, Pakistani, Yemeni, Syrian
  spEDS (*B4GALT7*)    Case report (2), case series (3)                          Good (4), fair (1)              M (15), F (13)                            0--46 y   Arab, Danish
  spEDS (*B3GALT6*)    Case report (1), case series (3)                          Fair (1), poor (3)              M (8), F (9), ND (8)                      0--34 y   Japanese, Singaporean, Vietnamese, Italian, Canadian, Brazilian, Iranian, South African
  spEDS (*SLC39A13*)   Case series (2)                                           Fair (1), poor (1)              M (4), F (4)                              2--22 y   Caucasian
  mcEDS (*CHST14*)     Case report (3), case series (8)                          Good (3), fair (2), poor (6)    M (16), F (20), ND (7)                    0--59 y   Hispanic, Pakistani, Curaçaoan, Moroccan, Miccosukee, Afghani, Turkish, Japanese, Asian, Indian, Dutch, Austrian
  mcEDS (*DSE*)        Case report (1)                                           Poor (1)                        M (1), F (2)[a](#t2-fn2){ref-type="fn"}   2--48 y   Indian, Spanish
  mEDS (*COL12A1*)     Case series (2)                                           Good (1), fair (1)              M (6), F (2)                              1--48 y   Turkish
  pEDS (*C1R/S*)       Case series (1)                                           Fair (1)                        M (25), F (30)                            ND        ND

BCS, brittle cornea syndrome; EDS, Ehlers-Danlos syndrome (for the definitions of the various subtypes of EDS, see Table 1); F, female; M, male; ND, not defined.

Reported in a case series of mcEDS (*CHST14*).

###### Vascular complications in nonvascular subtypes of the Eherls-Danlos syndrome

  EDS subtype             Affected      Multiple    Average/patient (range)  Hematoma   Intracranial hemorrhage   Arterial dissection   Arterial aneurysm   GI bleeding    Perioperative hemorrhage  Sporadic complication   Total
  -------------------- -------------- ------------ ------------------------- ---------- ------------------------- --------------------- ------------------- ------------- -------------------------- ----------------------- -------
  cEDS (*COL5A1/2)*     12/110 (11%)   1/110 (1%)         1.25 (1--4)        3          1                         6                     3                   1                         --             1                       15
  cEDS (*COL1A1)*        3/12 (25%)        --             1.00 (1--1)        --         --                        2                     1                   --                        --             --                      3
  clEDS (*TNXB*)        10/19 (53%)        --             1.00 (1--1)        10         --                        --                    --                  --                        --             --                      10
  cvEDS (*COL1A2*)       2/5 (40%)         --             1.00 (1--1)        --         --                        1                     --                  --                        1              --                      2
  aEDS (*COL1A1/2*)      1/17 (6%)         --             1.00 (1--1)        --         --                        --                    --                  --                        1              --                      1
  dEDS (*ADAMTS2*)       5/15 (33%)    2/15 (13%)         1.57 (1--2)        2          4                         --                    --                  --                        --             1                       7
  kEDS (*PLOD1*)         8/54 (15%)    1/54 (2%)          1.22 (1--3)        --         4                         5                     1                   --                        --             --                      10
  kEDS (*FKBP14*)        2/10 (20%)        --             1.00 (1--1)        --         --                        2                     --                  --                        --             --                      2
  spEDS (*B3GALT6*)      1/25 (4%)         --             1.00 (1--1)        --         1                         --                    --                  --                        --             --                      1
  spEDS (*SLC39A13)*     1/8 (13%)     1/8 (13%)          2.00 (2--2)        --         1                         --                    --                  --                        --             --                      1
  mcEDS (*CHST14*)      27/43 (63%)    8/43 (19%)         1.68 (1--6)        36         4                         --                    --                  --                        2              --                      42
  mcEDS (*DSE*)          2/3 (67%)         --             1.00 (1--1)        2          --                        --                    --                  --                        --             --                      2
  pEDS (*C1R/S*)         3/55 (6%)     1/55 (2%)          1.25 (1--2)        --         3                         --                    --                  --                        1              --                      4
  Total                      77            14                1.30            53         18                        16                    5                   1                         5              2                       100

EDS, Ehlers-Danlos syndrome (for the definitions of the various subtypes of EDS, see Table 1); GI, gastrointestinal.
